Saroglitazar
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
NAFLD
Conditions
NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias, Metabolic Syndrome
Trial Timeline
Jul 20, 2023 → Jun 10, 2025
NCT ID
NCT05872269About Saroglitazar
Saroglitazar is a approved stage product being developed by Zydus Lifesciences for NAFLD. The current trial status is unknown. This product is registered under clinical trial identifier NCT05872269. Target conditions include NAFLD, Obesity, Type 2 Diabetes.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05872269 | Approved | UNKNOWN |
Competing Products
15 competing products in NAFLD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 47 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| LCQ908 + placebo | Novartis | Phase 2 | 52 |
| Placebo + RO5093151 | Roche | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| Ketohexokinase inhibition | Pfizer | Phase 2 | 51 |
| PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination | Pfizer | Phase 2 | 51 |
| BMS-986036 | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-PNP + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Legalon® 140 mg | Viatris | Pre-clinical | 20 |
| Elobixibat + Placebo oral tablet | Ipsen | Phase 2 | 49 |
| Placebo + ISIS 703802 40 mg + ISIS 703802 80 mg + ISIS 703802 20 mg | Ionis Pharmaceuticals | Phase 2 | 49 |
| EDP 305 + Placebo | Enanta Pharmaceuticals | Phase 1 | 25 |